Cargando…

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2

Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic strategies for EGFR-TKIs. In this study, we ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Shengnan, Zhu, Ya, Wang, Siying, Zhang, Qinqiu, Zhang, Niu, Zou, Xiaoteng, Wei, Chenchen, Wang, Zhaoxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157544/ https://www.ncbi.nlm.nih.gov/pubmed/36471952 http://dx.doi.org/10.3724/abbs.2022176

Ejemplares similares

Overexpressed pseudogenes, DUXAP8 and DUXAP9, promote growth of renal cell carcinoma and serve as unfavorable prognostic biomarkers
por: Chen, Jing, et al.
Publicado: (2019)

The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer
por: Wei, Chen-Chen, et al.
Publicado: (2016)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Knockdown of pseudogene DUXAP8 expression in glioma suppresses tumor cell proliferation
por: Zhao, Xu, et al.
Publicado: (2020)

Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1
por: Chen, Zhenyao, et al.
Publicado: (2020)

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer
por: Zhao, Junjie, et al.
Publicado: (2022)

Pseudogene DUXAP10 acts as a diagnostic and prognostic marker and promotes cell proliferation by activating PI3K/AKT pathway in hepatocellular carcinoma
por: Yue, Chaosen, et al.
Publicado: (2019)

The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN
por: Lian, Yifan, et al.
Publicado: (2017)

n2oas 10
por: Boillot, J, et al.
Publicado: (1992)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018)

Over-expression of oncigenic pesudogene DUXAP10 promotes cell proliferation and invasion by regulating LATS1 and β-catenin in gastric cancer
por: Xu, Yongcan, et al.
Publicado: (2018)

Correction: Over-expression of oncigenic pesudogene DUXAP10 promotes cell proliferation and invasion by regulating LATS1 and β-catenin in gastric cancer
por: Xu, Yongcan, et al.
Publicado: (2023)

DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2
por: Lian, Yifan, et al.
Publicado: (2018)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing Krüppel-like factor 2 expression in human hepatocellular carcinoma
por: Jiang, Hao, et al.
Publicado: (2019)

The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression
por: Ma, Hong-wei, et al.
Publicado: (2016)

Pseudogene DUXAP8 Promotes Cell Proliferation and Migration of Hepatocellular Carcinoma by Sponging MiR-490-5p to Induce BUB1 Expression
por: Zhang, Haiping, et al.
Publicado: (2020)

Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44
por: Wang, He, et al.
Publicado: (2019)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis
por: Wei, Feifei, et al.
Publicado: (2020)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer
por: Zhang, Yujie, et al.
Publicado: (2020)

lncRNA DUXAP8 Facilitates Multiple Malignant Phenotypes and Resistance to PARP Inhibitor in HCC via Upregulating FOXM1
por: Hu, Yu, et al.
Publicado: (2020)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
por: Xiao, Yi, et al.
Publicado: (2018)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways
por: Han, Kun, et al.
Publicado: (2019)

Long non-coding RNA DUXAP10 exerts oncogenic properties in osteosarcoma by recruiting HuR to enhance SOX18 mRNA stability
por: Wang, Guantong, et al.
Publicado: (2022)

Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment
por: Sun, Xia, et al.
Publicado: (2021)

Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer
por: Li, Qiong, et al.
Publicado: (2015)

The Pseudogene DUXAP8 Promotes Colorectal Cancer Cell Proliferation, Invasion, and Migration by Inducing Epithelial-Mesenchymal Transition Through Interacting with EZH2 and H3K27me3
por: He, Wenjing, et al.
Publicado: (2020)

miR-196a Upregulation Contributes to Gefitinib Resistance through Inhibiting GLTP Expression
por: Liu, Bing-Jie, et al.
Publicado: (2022)

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
por: Xiao, Juanjuan, et al.
Publicado: (2019)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Endoplasmic Reticulum Stress Contributes to Gefitinib-Induced Apoptosis in Glioma
por: Chang, Cheng-Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fat9ei5p15ieahm1k9b05bg99u